FDA permits marketing of IDx-DR for automated detection of diabetic retinopathy in primary care

IDx, a privately-held AI diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo request to market IDx-DR, an AI-based diagnostic system for the autonomous detection of diabetic retinopathy, a leading cause of blindness. IDx-DR is the first autonomous, AI-based diagnostic system authorized for commercialization by the FDA.

KLAS Report Ranks MediRevv Second in Extended Business Office for Fourth Consecutive Year

THIS MARKS THE FIFTH YEAR THAT MEDIREVV HAS BEEN RANKED IN THE TOP THREE!

Coralville, IA – February 28, 2018– MediRevv, a healthcare revenue cycle management company, has been ranked second in the “Extended Business Office” category of the 2017/2018 Best in KLAS: Software and Services Report, February 2018.

MediRevv debuted on the KLAS list in 2013/2014 ranking third. In the 2014/2015 Best in KLAS report, they moved into the second position for the first time. Of note, MediRevv has held the second place ranking for four years running.

KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

CORALVILLE, Iowa, Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz™ for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.  Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).  

General Dynamics to Acquire CSRA for $9.6 Billion

  • Combination creates the premier provider of high-tech IT solutions to Government Technology Services market
  • With approximately $9.9 billion in revenue and strong double-digit EBITDA margins, the combined GDIT and CSRA is well-positioned to serve its customers’ current and evolving mission requirements
  • Expected to generate run-rate pre-tax cost synergies of approximately 2% of combined sales by 2020
  • Accretive to earnings and free cash flow per share in 2019

Voxello Announces their 4th Major Distribution Partnership

February 19, 2018 08:00 AM Eastern Standard Time

CORALVILLE, Iowa--(BUSINESS WIRE)--Today, Voxello, patient-provider engagement company specializing in solutions for critically ill patients, announced its fourth major distribution partnership with ASCC, Inc., a major U.S. distributor. ASCC partners with hospitals, long term care facilities and clinics in the Western Pennsylvania and Eastern Ohio regions and is now strategically positioned to distribute Voxello’s cutting-edge noddle® technology in this important market.

Ingredient Manufacturer Announces Non-GMO Project Verified Caffeine Ingredient

Austin, TX – Applied Food Sciences, Inc. (AFS) takes the next step in demonstrating complete transparency by getting four of its core ingredients Non-GMO Project Verified. The company’s PurCaf® organic caffeine headlines a list of innovative and sustainably sourced offerings by AFS.

 

PurCaf® Organic Caffeine – a 95% caffeine extract from organic green coffee beans

PurTea™ Organic Caffeine – a 90% caffeine extract from organic green tea leaves

JAVA.g™ – a polyphenolic blend of caffeine and antioxidants from green coffee beans

Pages

Subscribe to News & Announcements